ATHA logo

ATHA Athira Pharma, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$6.75
-0.44 (-6.12%)

Athira Pharma, Inc., a biopharmaceutical firm in advanced clinical development and based in Bothell, Washington, focuses on creating small molecule treatments designed to revitalize neuronal function and decelerate neurological decline. Its primary therapeutic candidate, ATH-1017, is a unique small molecule that modulates HGF/MET and is capable of crossing the blood-brain barrier. This compound is…

Market Cap: $26.62Mleonabio.com

Price

No data yet.

Social Signal Score

55
5d
—
30d
52
2 mentions
—
60d
56
7 mentions
—
90d
56
7 mentions
—
news: 7

Analyst Ratings

5 analysts
Holdconsensus
Strong Buy 0Buy 0Hold 5Sell 0Strong Sell 0
Avg price target$13.33+97.5%
Low $3Median $4High $33
Current Consensus

Revenue

$0.00
$0.00
Mar 2019Jun 2026

Analyst Estimates

FY2025
$-6.24
$-6.24–$-6.24
1 analysts
FY2026
$-4.87
$-5.03–$-4.71
2 analysts
FY2027
$-0.40
$-0.40–$-0.40
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Mark J. Litton
Sector
Healthcare
Industry
Biotechnology
Employees
26
Beta
2.80
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
-13.39
leonabio.com